This trial confirms the superiority of the combination melphalan and prednisone plus thalidomide over melphalan and prednisone alone for prolonging survival in very elderly patients with newly diagnosed myeloma. Toxicity was acceptable.
Dr. Alina Sadaf, MD recounts her experiences as a pediatric oncologist working with Afghan refugees in Lahore, Pakistan.
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant – Full Text View.
AbstractBackground. Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic
AbstractBackground. Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic
In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in…
In March 1998, Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AEs) to study drug. We investigate whether attribution…
Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid…
Blood Cancer Journal – In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
In March 1998, Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AEs) to study drug. We investigate whether attribution…
Use of surrogate end-points such as progression-free survival (PFS) and other time-to-event (TTE) end-points is common in multiple myeloma (MM) clinical trials. This systematic review…
